Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
Key Details
- 1Lucida Medical, a UK-based AI firm, raised $11.4 million in new funding.
- 2Their Prostate Intelligence (Pi) software uses MRI to help diagnose prostate cancer.
- 3The software is already deployed in up to 15 UK NHS hospitals.
- 4NHS invested around $3 million to use the platform, aiming for diagnoses within 28 days.
- 5The new funds will help pursue US FDA regulatory approval and expand to detect other clinical conditions.
Why It Matters
This funding supports efforts to scale AI-powered prostate cancer diagnosis, addressing critical radiology workforce shortages and speeding up patient pathways. US FDA approval could open access to broader markets and bring innovative diagnostic AI tools to more clinicians and patients.
Source
Radiology Business
Related News
•Radiology Business
CARPL.ai Raises $10M to Expand Radiology AI Marketplace
CARPL.ai secured $10M in Series A funding to expand its global radiology AI marketplace.
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.